As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger

While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be more mixed.